NAB2 Rabbit anti-Human, Mouse, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA527925
PA5-27925 targets NAB2 in IF and WB applications and shows reactivity with Human samples. The PA5-27925 immunogen is recombit fragment corresponding to a region within amino acids 4 and 416 of Human NAB2. Store product as a concentrated solution. Centrifuge briefly prior to opening the vial. For short-term storage (1-2 weeks), product can be stored at 4°C. For long-term storage, aliquot and store product at -20° C or below, avioiding multiple freeze-thaw cycles.This gene encodes a member of the family of NGFI-A binding (NAB) proteins, which function in the nucleus to repress transcription induced by some members of the EGR (early growth response) family of transactivators. NAB proteins can homo- or hetero-multimerize with other EGR or NAB proteins through a conserved N-terminal domain, and repress transcription through two partially redundant C-terminal domains. Transcriptional repression by the encoded protein is mediated in part by interactions with the nucleosome remodeling and deactylase (NuRD) complex. Alternatively spliced transcript variants have been described, but their biological validity has not been determined.
|Recombit fragment corresponding to a region within amino acids 4 and 416 of Human NAB2|
|Antigen affinity chromatography|
|Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot|
|PBS with 1% BSA, 20% glycerol and 0.01% thimerosal; pH 7|
|MADER, EGR-1-binding protein 2, EGR1 binding protein 2, NGFI-A-binding protein 2, melanoma-associated delayed early response protein|
|Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok